NSC23005 sodium

Research use only, not for human use.

A novel specific, effective p18 (p18INK4C) inhibitor that can selectively promote HSCs expansion with EC50 of 5.21 nM.

A novel specific, effective p18 (p18INK4C) inhibitor that can selectively promote HSCs expansion with EC50 of 5.21 nM; inhibits p18, and then activates CDK4/6, promotes HSCs expansion in both murine and human models; shows no activity in promoting the proliferation of leukemia cells, and no significant cytotoxicity toward 32D cells or HSCs.

NSC23005 sodium (Compound 40) is a novel class of INK4C (p18INK4C or p18) small molecule inhibitor (p18SMIs), which is initially found by in silico 3D screening. NSC23005 sodium shows the most potent bioactivity in hematopoietic stem cells (HSCs) expansion (ED50=5.21 nM). Notably, NSC23005 sodium does not show significant cytotoxicity toward 32D cells or HSCs, nor does it augment leukemia cell proliferation. NSC23005 sodium (ED50=5.21 nM), shows no activity in promoting the proliferation of leukemia cells.

NSC23005 sodium selectively promote HSCs division by inhibiting p18, thereby activating CDK4/6. NSC23005 sodium is a novel and effective p18 inhibitor in promoting HSCs expansion in both murine and human models.

NSC 23005 sodium | NSC-23005 sodium | p18-IN-40

Angiogenesis

CDK

p18INK4C

Cancer

——

1796596-46-7

305.33

C13H16NNaO4S

>98% (HPLC)

DMSO: 6.4 mg/mL (Need ultrasonic)

C1CCC(CC1)NS(=O)(=O)C2=CC=C(C=C2)C(=O)[O-].[Na+]

Benzoic acid, 4-[(cyclohexylamino)sulfonyl]-, sodium salt (1:1)

(-20℃)

With Ice Pack

≥ 2 years